...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Thoughts on ZCC

Toinv - The way I heard the story was that the existing shareholders of Zenith were going to diluted by a factore of 6 or 7 to the VC's that she was friendly with at the time. This is hear say. 

In order to see if there is any validity to that one could look at share structures of companies Dr Cherrington was with prior to taking the reins and then what it was at the time deals were made. Apparently deals were done but it was not at all in favour of the shareholders that funded the companies in the development of those technologies. The VC's walked away with smiles on their faces though.

 

Fact check that before believing a word of it though.

 

tada

 

Share
New Message
Please login to post a reply